Three years ago, Lilly gambled big on managed care with its acquisition of PCS--and lost. Its new strategy wagers almost as much on research, but this time the bets are hedged. As it aggressively builds infrastructure, it expands its program but limits its own flexibility and diminishes the likelihood that it can exploit all of its programs. Thus it will increasingly outlicense and sell assets it is not exploiting.
You may also be interested in...
Lilly's co-promotion with Boehringer Ingelheim of duloxetine is the first time the American company has signed a major marketing deal for one of its own products. The company notes the collaboration is part of its broad commitment to partnering and that the market is intensely competitive. But the choice of duloxetine--the launch of which may be delayed indefinitely because of manufacturing problems--also represents Lilly's lowest-risk option for subsidizing the launches, and maximizing the returns from, potentially eight new products over the next few years.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.